Target Discovery Collaboration and License Agreement Sample Contracts

TARGET DISCOVERY COLLABORATION AND LICENSE AGREEMENT BETWEEN GENE LOGIC INC. AND PROCTER & GAMBLE PHARMACEUTICALS, INC.

Target Discovery Collaboration and License Agreement • November 20th, 1997 • Gene Logic Inc • Services-commercial physical & biological research • Delaware

• Contract Type
  Target Discovery Collaboration and License Agreement
• Filed
  November 20th, 1997
• Company
  Gene Logic Inc
• Industry
  Services-commercial physical & biological research
• Jurisdiction
  Delaware

Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies

Target Discovery Collaboration and License Agreement • August 2nd, 2022

• Contract Type
  Target Discovery Collaboration and License Agreement
• Filed
  August 2nd, 2022

IRVING, Texas and MONROVIA, Calif., Aug. 2, 2022 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced today a multi-year strategic option and license agreement to research, develop and commercialize XmAb® bispecific antibodies directed against novel targets for the treatment of patients with cancer.